CARVEDILOL 3.125 MG
CARVEDILOL : 3.125 MG · DIN 02324504 · PRO DOC LIMITEE
Health Canada status: MARKETED
What is CARVEDILOL?
CARVEDILOL 3.125 MG contains CARVEDILOL : 3.125 MG. It is listed in the Health Canada Drug Product Database under DIN 02324504, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jun-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARVEDILOL used for?
Treatment of mild, moderate or severe heart failure of ischemic or non-ischemic origin to increase survival and reduce hospitalizations. Usually used with diuretics and ACE inhibitors.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02324504 |
|---|---|
| Brand name | CARVEDILOL |
| Generic / active ingredient | CARVEDILOL : 3.125 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 3.125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AG02 CARVEDILOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jun-2009 |
| Original market date | 2009-06-12 00:00:00 |
How is it administered?
Initial: 3.125 mg bid for 2 weeks. If tolerated, titrate to 6.25, 12.5, and 25 mg bid at 2-week intervals. Take with food. Max dose: 25 mg bid. Gradual reduction over 2 weeks for discontinuation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in the provided text (standard House Standard mentioned).
How is it supplied?
HDPE bottles of 100 tablets.
Contraindications
Decompensated cardiac failure requiring IV inotropic therapy; bronchial asthma/bronchospasm; 2nd/3rd degree AV block or sick sinus syndrome; cardiogenic shock; severe hypotension/bradycardia.
Warnings and precautions
Beta-blockers can cause worsening heart failure. Avoid abrupt cessation. Risk of hypotension, bradycardia, and hepatotoxicity. May mask symptoms of hypoglycemia and hyperthyroidism.
Is CARVEDILOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AG02 CARVEDILOL. 28 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CARVEDILOL | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02418517 |
| AURO-CARVEDILOL | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02418525 |
| AURO-CARVEDILOL | 3.125 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02418495 |
| AURO-CARVEDILOL | 6.25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02418509 |
| CARVEDILOL | 12.5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02248754 |
| CARVEDILOL | 12.5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02364948 |
| CARVEDILOL | 12.5 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02324520 |
| CARVEDILOL | 25 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02364956 |
| CARVEDILOL | 25 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02248755 |
| CARVEDILOL | 25.0 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02324539 |
Who else supplies CARVEDILOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARVEDILOL appears in 2015 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.